Deutsch English Français

Contact

EP2763698

European procedure

Quick help

Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...

News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...

Extract from the Register of European Patents

EP About this file: EP2763698

EP2763698 - LIPOSOME COMPOSITIONS COMPRISING AN ADJUVANT THAT ACTIVATES OR INCREASES THE ACTIVITY OF TLR2 AND USES THEREOF [Right-click to bookmark this link]
Status	No opposition filed within time limit Status updated on 08.10.2021 Database last updated on 19.07.2024
Former	The patent has been granted Status updated on 30.10.2020
Former	Grant of patent is intended Status updated on 31.08.2020
Former	Examination is in progress Status updated on 20.07.2020
Former	Grant of patent is intended Status updated on 11.03.2020
Former	Examination is in progress Status updated on 04.08.2017
Most recent event Tooltip	27.04.2024	Lapse of the patent in a contracting state New state(s): MK	published on 29.05.2024 [2024/22]
Applicant(s)	For all designated states ImmunoVaccine Technologies Inc. 130 Eileen Stubbs Avenue, Suite 19 Dartmouth, Nova Scotia B3B 2C4 / CA
	[2020/35]
Former [2014/33]	For all designated states ImmunoVaccine Technologies Inc. 1344 Summer Street, Suite 412 Halifax, Nova Scotia B3H 0A8 / CA
Inventor(s)	01 / MANSOUR, Marc 17 Alton Drive Halifax Nova Scotia B3N 1L8 / CA
	02 / MACDONALD, Lisa Diana 54 Rufus Ave. Halifax Nova Scotia B3N 2L7 / CA
	03 / WEIR, Genevieve Mary 468 Spring Avenue Dartmouth Nova Scotia B2W 1X8 / CA
	04 / SAMMATUR, Leeladhar 5225 Archway Irvine California 92618 / US
	05 / SHARP, Kendall 6038 Leeds Street Halifax Nova Scotia B3K 2T5 / CA
	[2020/35]
Former [2014/34]	01 / MANSOUR, Marc 17 Alton Drive Halifax Nova Scotia B3N 1L8 / CA
	02 / MACDONALD, Lisa Diana 54 Rufus Ave. Halifax Nova Scotia B3N 2L7 / CA
	03 / WEIR, Genevieve Mary 468 Spring Avenue Dartmouth Nova Scotia B2W 1X8 / CA
	04 / SAMMATUR, Leeladhar 46 Fathom Court Halifax Nova Scotia B3M 0A7 / CA
	05 / SHARP, Kendall 6038 Leeds Street Halifax Nova Scotia B3K 2T5 / CA
Former [2014/33]	01 / MANSOUR, Marc c/o Immunovaccine Technologies Inc. 1819 Granville Street Suite 303 Halifax$ Nova Scotia B3J 3R1 / CA
	02 / MACDONALD, Lisa Diana c/o Immunovaccine Technologies Inc. 1819 Granville Street Suite 303 Halifax Nova Scotia B3J 3R1 / CA
	03 / WEIR, Genevieve Mary c/o Immunovaccine Technologies Inc. 1819 Granville Street Suite 303 Halifax Nova Scotia B3J 3R1 / CA
	04 / SAMMATUR, Leeladhar c/o Immunovaccine Technologies Inc. 1819 Granville Street Suite 303 Halifax Nova Scotia B3J 3R1 / CA
	05 / SHARP, Kendall c/o Immunovaccine Technologies Inc. 1819 Granville Street Suite 303 Halifax Nova Scotia B3J 3R1 / CA
Representative(s)	Comoglio, Elena, et al Jacobacci & Partners S.p.A. Corso Emilia 8 10152 Torino / IT
	[2020/49]
Former [2014/33]	Comoglio, Elena, et al Jacobacci & Partners S.p.A. Corso Emilia 8 10152 Torino / IT
Application number, filing date	12838879.0	05.10.2012
	[2020/49]
	WO2012CA50705
Priority number, date	US201161544020P	06.10.2011 Original published format: US 201161544020 P
	[2014/33]
Filing language	EN
Procedural language	EN
Publication	Type:	A1 Application with search report
	No.:	WO2013049941
	Date:	11.04.2013
	Language:	EN
	[2013/15]
	Type:	A1 Application with search report
	No.:	EP2763698
	Date:	13.08.2014
	Language:	EN
	The application published by WIPO in one of the EPO official languages on 11.04.2013 takes the place of the publication of the European patent application.
	[2014/33]
	Type:	B1 Patent specification
	No.:	EP2763698
	Date:	02.12.2020
	Language:	EN
	[2020/49]
Search report(s)	International search report - published on:	CA	11.04.2013
	(Supplementary) European search report - dispatched on:	EP	07.07.2015
Classification	IPC:	A61K39/39, A61K9/127, A61P31/00, A61P37/04, A61K39/07, A61K39/02, A61K39/12, A61K39/145, A61K39/00	[2015/11]
	CPC:	A61K9/127 (EP,US); A61K39/145 (US); A61K39/07 (EP,US); A61K39/099 (EP,US); A61K39/12 (EP,US); A61K39/39 (EP,US); (+) A61P25/28 (EP); A61P31/00 (EP); A61P31/04 (EP); A61P31/12 (EP); A61P31/16 (EP); A61P35/00 (EP); A61P37/04 (EP); A61P37/08 (EP); A61P43/00 (EP); A61K2039/5252 (EP,US); A61K2039/55511 (EP,US); A61K2039/55555 (EP,US); A61K2039/55566 (EP,US); C12N2760/16134 (EP,US) (-)
	Former IPC [2014/33]	A61K39/39, A61K9/127, A61P31/00, A61P37/04
Designated contracting states	AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2014/33]
Extension states	BA	Not yet paid
	ME	Not yet paid
Title	German:	LIPOSOMZUSAMMENSETZUNGEN MIT EINEM ADJUVANS ZUR AKTIVIERUNG ODER STEIGERUNG DER AKTIVITÄT VON TLR2 UND VERWENDUNGEN DAVON	[2014/33]
	English:	LIPOSOME COMPOSITIONS COMPRISING AN ADJUVANT THAT ACTIVATES OR INCREASES THE ACTIVITY OF TLR2 AND USES THEREOF	[2014/33]
	French:	COMPOSITIONS LIPOSOMALES COMPRENANT UN ADJUVANT QUI ACTIVE OU ACCROÎT L'ACTIVITÉ DE TLR2 ET UTILISATIONS ASSOCIÉES	[2014/33]
Entry into regional phase	06.05.2014	National basic fee paid
	06.05.2014	Search fee paid
	06.05.2014	Designation fee(s) paid
	06.05.2014	Examination fee paid
Examination procedure	06.05.2014	Examination requested [2014/33]
	27.01.2016	Amendment by applicant (claims and/or description)
	04.08.2017	Despatch of a communication from the examining division (Time limit: M04)
	12.12.2017	Reply to a communication from the examining division
	07.05.2018	Despatch of a communication from the examining division (Time limit: M06)
	14.11.2018	Reply to a communication from the examining division
	12.11.2019	Cancellation of oral proceeding that was planned for 14.11.2019
	14.11.2019	Date of oral proceedings (cancelled)
	12.03.2020	Communication of intention to grant the patent
	17.07.2020	Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
	17.07.2020	Fee for grant paid
	17.07.2020	Fee for publishing/printing paid
	31.08.2020	Information about intention to grant a patent
	31.08.2020	Receipt of the translation of the claim(s)
Divisional application(s)	The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is 04.08.2017
Opposition(s)	03.09.2021	No opposition filed within time limit [2021/45]
Fees paid	Renewal fee
	17.10.2014	Renewal fee patent year 03
	23.09.2015	Renewal fee patent year 04
	07.10.2016	Renewal fee patent year 05
	12.10.2017	Renewal fee patent year 06
	25.09.2018	Renewal fee patent year 07
	24.09.2019	Renewal fee patent year 08
	23.10.2020	Renewal fee patent year 09
Opt-out from the exclusive Tooltip competence of the Unified Patent Court	See the Register of the Unified Patent Court for opt-out data
	Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition Tooltip	HU	05.10.2012
	AL	02.12.2020
	AT	02.12.2020
	CY	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	MC	02.12.2020
	MK	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
	[2024/22]
Former [2023/28]	HU	05.10.2012
	AL	02.12.2020
	AT	02.12.2020
	CY	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	MC	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2023/24]	AL	02.12.2020
	AT	02.12.2020
	CY	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	MC	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2022/33]	AL	02.12.2020
	AT	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	MC	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2022/23]	AL	02.12.2020
	AT	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2022/10]	AL	02.12.2020
	AT	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	PT	05.04.2021
Former [2021/49]	AL	02.12.2020
	AT	02.12.2020
	CZ	02.12.2020
	DK	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SI	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2021/45]	AL	02.12.2020
	AT	02.12.2020
	CZ	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2021/42]	AT	02.12.2020
	CZ	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	IS	02.04.2021
	PT	05.04.2021
Former [2021/37]	AT	02.12.2020
	CZ	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	PT	05.04.2021
Former [2021/36]	CZ	02.12.2020
	EE	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	PT	05.04.2021
Former [2021/35]	CZ	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RO	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SK	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	PT	05.04.2021
Former [2021/34]	CZ	02.12.2020
	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	PT	05.04.2021
Former [2021/33]	FI	02.12.2020
	HR	02.12.2020
	LT	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
	PT	05.04.2021
Former [2021/32]	FI	02.12.2020
	HR	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	SM	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
Former [2021/28]	FI	02.12.2020
	HR	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
Former [2021/25]	FI	02.12.2020
	LV	02.12.2020
	PL	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
Former [2021/24]	FI	02.12.2020
	LV	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	BG	02.03.2021
	NO	02.03.2021
	GR	03.03.2021
Former [2021/23]	FI	02.12.2020
	LV	02.12.2020
	RS	02.12.2020
	SE	02.12.2020
	NO	02.03.2021
	GR	03.03.2021
Former [2021/22]	FI	02.12.2020
	RS	02.12.2020
	NO	02.03.2021
Former [2021/20]	FI	02.12.2020
Documents cited:	Search	[XYI] - SUZANNE M. BAL ET AL, "Co-encapsulation of antigen and Toll-like receptor ligand in cationic liposomes affects the quality of the immune response in mice after intradermal vaccination", VACCINE, (20110101), vol. 29, no. 5, doi:10.1016/j.vaccine.2010.11.061, ISSN 0264-410X, pages 1045 - 1052, XP055165405 [X] 1-6,8,9,12-17 * abstract * * paragraphs [02.3] , [ 2.6] , [ 2.7]; figure 5 * * paragraph [0004] * [Y] 1-17 [I] 1-17 DOI: http://dx.doi.org/10.1016/j.vaccine.2010.11.061
		[XYI] - M. MANSOUR ET AL, "Improved Efficacy of a Licensed Acellular Pertussis Vaccine, Reformulated in an Adjuvant Emulsion of Liposomes in Oil, in a Murine Model", CLINICAL AND VACCINE IMMUNOLOGY, (20070822), vol. 14, no. 10, doi:10.1128/CVI.00143-07, ISSN 1556-6811, pages 1381 - 1383, XP055025140 [X] 1-10,12-17 * page 1383 * [Y] 1-17 [I] 1-17 DOI: http://dx.doi.org/10.1128/CVI.00143-07
		[IY] - DAFTARIAN P ET AL, "Eradication of established HPV 16-expressing tumors by a single administration of a vaccine composed of a liposome-encapsulated CTL-T helper fusion peptide in a water-in-oil emulsion", VACCINE, ELSEVIER LTD, GB, vol. 24, no. 24, doi:10.1016/J.VACCINE.2006.03.079, ISSN 0264-410X, (20060612), pages 5235 - 5244, (20060612), XP028010677 [I] 1-10,12,13,16 * abstract * * material & methods * [Y] 1-17 DOI: http://dx.doi.org/10.1016/j.vaccine.2006.03.079
		[YP] - "Biochemicals Catalogue 2012 NEW: Tools for Toll-like receptor research Lipopeptides for Toll-like receptor 1 and 2 research Pam Cys-SKKKK and analogues 3", (20120328), URL: http://web.archive.org/web/20120328203424/http://www.microcollections.de/pdf/EMC Biochemicals 2012.pdf, (20150611), XP055195149 [YP] 1-17 * page 5 - page 7 *
		[Y] - WILLIAM A ROSE ET AL, "FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection", VIROLOGY JOURNAL, (20090101), vol. 6, no. 1, doi:10.1186/1743-422X-6-195, ISSN 1743-422X, page 195, XP055194654 [Y] 1-17 * abstract * DOI: http://dx.doi.org/10.1186/1743-422X-6-195
		[Y] - FOLKERT STEINHAGEN ET AL, "TLR-based immune adjuvants", VACCINE, ELSEVIER LTD, GB, vol. 29, no. 17, doi:10.1016/J.VACCINE.2010.08.002, ISSN 0264-410X, (20100801), pages 3341 - 3355, (20100807), XP028380413 [Y] 1-17 * p 3342, par 2 * DOI: http://dx.doi.org/10.1016/j.vaccine.2010.08.002
		[A] - KARKADA M ET AL, "A liposome-based platform, VacciMax<(>R), and its modified water-free platform DepoVax(TM) enhance efficacy of in vivo nucleic acid delivery", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 38, ISSN 0264-410X, (20100831), pages 6176 - 6182, (20100723), XP027211923 [A] 1-17 * the whole document *
		[A] - WEIGUANG ZENG ET AL, "Structural requirement for the agonist activity of the TLR2 ligand Pam2Cys", AMINO ACIDS ; THE FORUM FOR AMINO ACID AND PROTEIN RESEARCH, SPRINGER-VERLAG, VI, (20100121), vol. 39, no. 2, ISSN 1438-2199, pages 471 - 480, XP019853783 [A] 1-17 * the whole document *
		[A] - MOYLE PETER M ET AL, "Self-adjuvanting lipopeptide vaccines", CURRENT MEDICINAL CHEMISTRY, BENTHAM SCIENCE PUBLISHERS, NL, (20080101), vol. 15, no. 5, doi:10.2174/092986708783503249, ISSN 0929-8673, pages 506 - 516, XP009104575 [A] 1-17 * the whole document * DOI: http://dx.doi.org/10.2174/092986708783503249
		[A] - "Bacterial lipopeptides activate Toll-like receptors 1,2 and 6", Bacterial lipopeptides activate Toll-like receptors 1,2 and 6, (20030416), XP055195656 [A] 1 * abstract *
	International search	[X]CA2542212 (IMMUNOVACCINE TECHNOLOGIES INC [CA]);
		[X]CA2622464 (IMMUNOVACCINE TECHNOLOGIES INC [CA]);
		[X] - HEURTAULT, B. ET AL., "Liposome-based systems for anti-tumor vaccination: influence of lipopeptide adjuvants.", J. LIPOSOME RESEARCH., (2006), vol. 16, pages 205 - 213, XP008173217 DOI: http://dx.doi.org/10.1080/08982100600848736
		[Y] - MANSOUR, M. ET AL., "Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model.", CLIN. VACCINE IMMUNOL., (200710), vol. 14, no. 10, pages 1381 - 1383, XP055025140 DOI: http://dx.doi.org/10.1128/CVI.00143-07
		[Y] - THUENG-IN, K. ET AL., "Heterosubtypic immunity to influenza mediated by liposome adjuvanted H5N1 recombinant protein vaccines.", VACCINE., (2010), vol. 28, pages 6765 - 6777, XP027267150
	Examination	WO2007041832
		WO2009072767
		WO2009146523
		US2010209452
		- Martina Barrenschee ET AL, "Effects of the TLR2 Agonists MALP-2 and Pam3Cys in Isolated Mouse Lungs", PLoS ONE, (20101116), vol. 5, no. 11, doi:10.1371/journal.pone.0013889, page e13889, XP055394881 DOI: http://dx.doi.org/10.1371/journal.pone.0013889
		- KARKADA M ET AL, "A liposome-based platform, VacciMax^(R), and its modified water-free platform DepoVax(TM) enhance efficacy of in vivo nucleic acid delivery", VACCINE, ELSEVIER, AMSTERDAM, NL, vol. 28, no. 38, ISSN 0264-410X, (20100831), pages 6176 - 6182, (20100723), XP027211923
		- GENEVIEVE M. WEIR ET AL, "Combination of poly I:C and Pam3CSK4 enhances activation of B cells in vitro and boosts antibody responses to protein vaccines in vivo", PLOS ONE, (20170629), vol. 12, no. 6, doi:10.1371/journal.pone.0180073, page e0180073, XP055562079 DOI: http://dx.doi.org/10.1371/journal.pone.0180073
		- Folkert Steinhagen ET AL, "TLR-based immune adjuvants", Vaccine, AMSTERDAM, NL, (20110401), vol. 29, no. 17, doi:10.1016/j.vaccine.2010.08.002, ISSN 0264-410X, pages 3341 - 3355, XP055562166 DOI: http://dx.doi.org/10.1016/j.vaccine.2010.08.002
		- BESSLER W G ET AL, "BACTERIAL CELL WALL COMPONENTS AS IMMUNOMODULATORS-I LIPOPETPTIDES AS ADJUVANTS FRO PARENTERAL AND ORAL IMMUNIZATION", INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, ELMSFORD,NY, US, (19970101), vol. 19, no. 9/10, doi:10.1016/S0192-0561(97)00054-4, ISSN 0192-0561, pages 547 - 550, XP001015712 DOI: http://dx.doi.org/10.1016/S0192-0561(97)00054-4
		- Steven A. Rosenberg ET AL, "Different Adjuvanticity of Incomplete Freund?s Adjuvant Derived From Beef or Vegetable Components in Melanoma Patients Immunized With a Peptide Vaccine", Journal of Immunotherapy, (20100701), vol. 33, no. 6, doi:10.1097/CJI.0b013e3181dac9de, ISSN 1524-9557, pages 626 - 629, XP055097740 DOI: http://dx.doi.org/10.1097/CJI.0b013e3181dac9de
		- KARKADA MOHAN ET AL, "A novel breast/ovarian cancer peptide vaccine platform that promotes specific type-1 but not Treg/Tr1-type responses", JOURNAL OF IMMUNOTHERAPY, RAVEN PRESS, NEW YORK, NY, US, (20100401), vol. 33, no. 3, doi:10.1097/CJI.0B013E3181C1F1E9, ISSN 1053-8550, pages 250 - 261, XP008152974 DOI: http://dx.doi.org/10.1097/CJI.0b013e3181c1f1e9
		- FRANSEN F ET AL, "Agonists of toll-like receptors 3, 4, 7, and 9 are candidates for use as adjuvants in an outer membrane vaccine against Neisseria meningitidis serogroup B", INFECTION AND IMMUNITY, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 75, no. 12, doi:10.1128/IAI.00846-07, ISSN 0019-9567, (20071201), pages 5939 - 5946, (20071001), XP002717175 DOI: http://dx.doi.org/10.1128/IAI.00846-07

The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.

Legal notice
Terms of use
24.1.24; 34p